<DOC>
	<DOCNO>NCT00856154</DOCNO>
	<brief_summary>Phase I test concept study : In attempt induce new immunity HIV-1 untreated HIV-1 infection investigator identify relatively immune silent immune subdominant HLA-A2-restricted HIV-1 CTL epitopes fit individual HLA-A2 tissue type ( 50 % people Denmark ) . Immunising conserved epitope could induce new immunity lower viral load patient live long AIDS Antiviral medicine lower viral load limit spread population . As adjuvant investigator use patient ' autologous Dendritic Cells generate blood cell vitro . 12 healthy male HIV-1 infected therapy individual use therapeutic vaccination test safety induction new cellular CD8 CD4 T-cell immunity .</brief_summary>
	<brief_title>Vaccination With Autologous Dendritic Cells Pulsed With HIV-Antigens Treatment Patients With Chronic HIV-Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>HIV positive male Viral load &gt; 1000/ml CD4 count &gt; 300 HLAA2 tissue type 1850 year age Able follow instruction Informed consent Treated experimental vaccine immune modulatig medicine Other chronic infectious disease Allergy autoimmune disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>HLA-A2</keyword>
	<keyword>Therapeutic</keyword>
	<keyword>Vaccine</keyword>
	<keyword>treatment vaccine</keyword>
	<keyword>treatment naive</keyword>
</DOC>